Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Spruce Biosciences (Nasdaq: SPRB), a late-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's CEO, Javier Szwarcberg, M.D., M.P.H., is scheduled to present on September 10, 2024, at 4:30 p.m. ET.
Spruce Biosciences focuses on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical needs. Interested parties can access the live webcast of the presentation through a provided link. An archived version of the webcast will be available on the company's investor relations website for approximately 90 days after the event.
Spruce Biosciences (Nasdaq: SPRB), un'azienda biofarmaceutica in fase avanzata, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. Il CEO dell'azienda, Javier Szwarcberg, M.D., M.P.H., è programmato per presentare il 10 settembre 2024, alle 16:30 ET.
Spruce Biosciences si concentra sullo sviluppo e sulla commercializzazione di nuove terapie per disturbi endocrini e neurologici con esigenze mediche significative insoddisfatte. Le parti interessate possono accedere alla trasmissione in diretta della presentazione tramite un link fornito. Una versione archiviata della trasmissione sarà disponibile sul sito web per le relazioni con gli investitori dell'azienda per circa 90 giorni dopo l'evento.
Spruce Biosciences (Nasdaq: SPRB), una empresa biofarmacéutica en fase avanzada, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El CEO de la compañía, Javier Szwarcberg, M.D., M.P.H., está programado para presentar el 10 de septiembre de 2024, a las 4:30 p.m. ET.
Spruce Biosciences se centra en desarrollar y comercializar nuevas terapias para trastornos endocrinos y neurológicos con necesidades médicas insatisfechas significativas. Las partes interesadas pueden acceder a la transmisión en vivo de la presentación a través de un enlace proporcionado. Una versión archivada de la transmisión estará disponible en el sitio web de relaciones con inversores de la compañía durante aproximadamente 90 días después del evento.
Spruce Biosciences (Nasdaq: SPRB)는 후기 단계의 생물 제약 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 회사의 CEO인 Javier Szwarcberg, M.D., M.P.H.가 2024년 9월 10일 오후 4:30 ET에 발표할 예정입니다.
Spruce Biosciences는 내분비 및 신경 장애에 대한 새로운 치료 방법 개발 및 상용화에 집중하고 있으며, 큰 의학적 필요가 있습니다. 이해관계자들은 제공된 링크를 통해 발표의 생중계를 접속할 수 있습니다. 발표의 아카이브 버전은 행사 후 약 90일 동안 회사의 투자자 관계 웹사이트에서 이용 가능할 것입니다.
Spruce Biosciences (Nasdaq: SPRB), une entreprise biopharmaceutique en phase avancée, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. Le PDG de l'entreprise, Javier Szwarcberg, M.D., M.P.H., est prévu pour présenter le 10 septembre 2024, à 16h30 ET.
Spruce Biosciences se concentre sur le développement et la commercialisation de nouvelles thérapies pour des troubles endocriniens et neurologiques ayant des besoins médicaux importants non satisfaits. Les parties intéressées peuvent accéder à la diffusion en direct de la présentation via un lien fourni. Une version archivée de la diffusion sera disponible sur le site Web des relations avec les investisseurs de l'entreprise pendant environ 90 jours après l'événement.
Spruce Biosciences (Nasdaq: SPRB), ein biopharmazeutisches Unternehmen in der späten Phase, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Der CEO des Unternehmens, Javier Szwarcberg, M.D., M.P.H., wird am 10. September 2024, um 16:30 Uhr ET präsentieren.
Spruce Biosciences konzentriert sich auf die Entwicklung und Vermarktung neuartiger Therapien für endokrine und neurologische Erkrankungen mit erheblichen ungedeckten medizinischen Bedürfnissen. Interessierte können die Live-Übertragung der Präsentation über einen bereitgestellten Link abrufen. Eine archivierte Version der Übertragung wird auf der Website der Unternehmensinvestorenbeziehungen etwa 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 90 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need. Spruce is developing its product candidate, tildacerfont, an oral, second-generation CRF1 receptor antagonist, for the treatment of congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS) and major depressive disorder (MDD). To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903641742/en/
Media
Katie Beach Oltsik
Inizio Evoke Comms
(937) 232-4889
Katherine.Beach@inizioevoke.com
media@sprucebio.com
Investors
Samir Gharib
President and CFO
Spruce Biosciences, Inc.
investors@sprucebio.com
Source: Spruce Biosciences, Inc.
FAQ
When is Spruce Biosciences (SPRB) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Spruce Biosciences (SPRB) at the investment conference?
How can investors access Spruce Biosciences' (SPRB) presentation at the H.C. Wainwright conference?
What is the focus of Spruce Biosciences (SPRB) as a company?
